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THE bacterial vaccine Corynebacterium
parvum (C. parvum) is currently being
used as adjuvant non-specific active
immunotherapy following surgery for
colorectal cancer in humans (Macdonald,
1976). However, a recent computer-assis-
ted literature search of Index Medicus
("Medline") conducted by us (in August
1977, covering the preceding 3 years)
failed to reveal any reports of its use in a
comparable animal model of colorectal
cancer. We wish to report the results of
such a study. Our findings, after 36 weeks
of observation, indicate that C. parvrum
administration to rats bearing dimethyl-
hydrazine (DMH)-induced colonic cancers
significantly increases mortality, results
in greater incidence of metastases and
greater numbers of colonic tumours, and
causes earlier tumour presentation.
The chronic administration of DMH to
rats results in nearly 100% incidence of
colonic tumours within 5-7 months (New-
berne and Rogers, 1973; Pozharisski,
1975). The induced colonic cancer presents
with rectal bleeding, diarrhoea, obstruc-
tion and intussusception, and closely
parallels the human disease in its gross and
microscopic pathology (Newberne and
Rogers, 1973; Pozharisski, 1975; Filipe,
1975) and in the implication of dietary
factors in the promotion of carcinogenesis
(Rogers and Newberne, 1975; Castleden,
1977). Immunobiologically, there are im-
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portant similarities. The tumours are
primary, autochthonous adenocarcino-
mata with a relatively long latent period,
slow-growing course and late metastases.
In rats, carcinofoetal antigens (Martin
et al., 1975) and surface antigens, anala-
gous to these demonstrated on human
colon carcinoma cells, have been identified
serologically (Garmaise et al., 1975) and
shown to induce lymphocyte-mediated
cytotoxicity (Steele and Sjogren, 1974).
Experiments with tumour isograft chal-
lenge indicate that these in vitro tumour
markers can function in vivo as tumour-
rejection antigens (Steele and Sjogren,
1977), and cell-mediated antitumour im-
munity has been demonstrated in tumour
bearers (Sjogren and Steele, 1975).
C. parvum was administered to DMH-
treated rats because it has been shown to
be an effective antitumour agent in
several animal tumour models (reviewed
by Scott, 1974; Halpern, 1973) and
because this agent is currently undergoing
clinical investigation in patients with
Duke's stages B, C and D colorectal cancer
(Macdonald, 1976). It is thought that the
widespread macrophage activation which
follows its systemic administration (Oli-
votto and Bomford, 1974) is responsible
for the antitumour action. However, the
immunological action of this material is
complex, as its administration is followed
by other effects, such as suppression of
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TABLE.-Effect of C. parvum on Rats with DMH-induced
Colonic Cancers (10 Rats/Group)
Group
A
B
C
D
Treatment
DMH 20 mg/kg/week s.c. for 20 weeks
DMH as above plus C. parvum 3-5 mg
i.p. at 3-weekly intervals x 4 doses
(weeks 13, 16, 19 and 22)
C. parvum as above (control)
Saline 1 ml/kg/week s.c. (control)
Situationi 36 wveeks after first, injectionl of DMNtH
Week of first No. of animals No. of animals
presentation dea(l* with metastases
23, 30, 33 3 l
16, 19, 2(0, 21,
21, 21, 23, 25, 32 6
0
0
* No deaths attributable to causes other thain cancer.
t 2 of these deaths were spontaneous.
Statistical analysis: mortality of Group A vs Group 13: /2=6-92, 1 (d.f., 0)005<JU<(00-1.
cell-mediated immunity (Scott, 1972),
increased differentiation and proliferation
of antigen-triggered lymphocytes (Lancet,
1976b) and amplified lymphocyte trapping
(Frost and Lance, 1973).
BCG, another macrophage-activating
agent, has been shown to delay tumour
onset and reduce tumour incidence in
rodents given other carcinogens (Piessens
et al., 1970; Lavrin et al., 1973), but it did
not alter the rate of development nor
incidence of colonic tumours when given
to DMH-treated rats (Rogers and Gildin,
1975; Rogers and Newberne, 1975).
Forty female Wistar rats of approxi-
mately 150 g were divided into 4 groups of
10 animals and injected according to the
regimen set out in the Table. The DMH
dosage and method ofpreparation was that
of Filipe (1975).
C. parvum (CN 6134, Batch PX 383,
heat-killed, no added preservative, 7 mg
dry wt/ml) was obtained from Wellcome
Research Laboratories, Beckenham, Kent.
As the immunological effects of this agent
may be profoundly affected by dose,
timing and route of administration (Bom-
ford, 1977; Lancet, 1976b) the rationale
behind the regimen selected for this
experiment is detailed: Bomford (1.975)
has shown, in a non-specific immuno-
therapy situation, that tumour growth
was retarded by the highest concentration
of C. parvumn tested (350,g for 15-20 g
mouse). Accordingly, this dosage was
selected and related to rat body wt (i.e.
3 5 mg for 150-200 g rat) (Bomford,
personal communication). The i.p. route
was chosen because (i) i.p. or i.v. C. parvum
more effectively inhibits tumour growth
than s.c. (Fisher et al., 1973) (ii) it has
been shown (Scott, 1975) that lymph-
node-mediated contact between C. parvum
and tumour antigens is necessary for
optimum effect and (iii) this route has
been used painlessly in humans (Israel and
Edelstein, 1977) with C. parvum being
given daily for 1-14 days. It was admini-
stered 3-weekly to approximate to the
monthly frequency of some human trials
and to incorporate the effects of the peak
splenic (Day 16) and lymph node (Day 7)
enlargement observed by Milas et al.
(1975) using C. granulosum. However, the
C. parvum treatment was stopped when a
DMH-pretreated group (Group B) failed
to gain weight after the 4th dose. In
contrast, the animals in all other groups
maintained a progressive increase in
weight.
Administration was started 13 weeks
after the first injection of DM1H, so as to
provide a population of activated macro-
phages at a time when the rat colonic
epithelial cells are known to show abnor-
mal morphological changes (ranging from
cellular dysplasia to carcinoma in situ)
both histologically (Filipe, 1975; Pozharis-
ski, 1975) and electronmicroscopically
(Barkla and Tutton, 1977). The postulated
phenomenon of macrophage-mediated
immunosurveillance (Lancet, 1 976a; Alex-
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ander, 1976) would, in theory, be facili-
tated by the presence of activated
macrophages at this time, and the tuimour
burden would also be minimal.
Animals were housed in subgroups of 5
in suspended cages, fed standard diet
(41B) and water ad lib, and weighed
weekly. They were inspected daily for the
signs of tumour presentation previously
cited, and were isolated when these were
noted, to prevent cannibalization. When
deemed "terminal" by objective but
humane criteria (namely, 5 successive
weight losses of > 10 g/week after presen-
tation, loss of >25% of body weight in
one week, gross ascites with emaciation
and/or respiratory difficulties) they were
painlessly killed. Full postmortem exami-
nations, including histology, were per-
formed on all animals.
Mortality was analysed by the Logrank
method of Peto et al. (1977).
The results, summarized in the Table
and Fig., show that, whereas all control
animals were still alive at 36 weeks,
animals receiving DMH plus C. parvrum
(Group B) showed a significantly increased
mortality (P<001) compared with (Group
A animals, given DMH alone. All animals
examined postmortem had malignant colo-
nic tumours, but the C. parvum-treated
group showed earlier signs of tumour
presentation, greater numbers of colonic
tumnours per animal (mean A s.e. 129 ±
4
C!)
0 20 22 24 26 28 30 32 34
TIME FROM FIRST DMH INJECTION (WEEKS)
Fi.- Percentage survival as a fuinctioni of
time after first injection of DMIH.
........ Group D (saline control)
Group C (C. parvum control)
Group A (DAIH alone);
GIoup B (DAIH+C. parvtrn?).
22 vs 7 7 + 1.8) and a greater incidenice of
metastases (to regional nodes, peritoneum,
omentum and liver) than untreated ani-
mals. The extent and incidence of meta-
stases were particularly striking, since
metastases are generally rare in this model
system (Rogers and Newberne, 1975). It is
also interesting to note that 4/9 (44o%) of
the C. parvum-treated animals developed
primary cancers at a site other than the
intestine (i.e. squamous-cell carcinomas
of the ear canal). The incidence of ear-
canal tumours was less than 10% in other
reports commenting on this phenomenon
(Nigro et al., 1973; Martin et al., 1973)
and only animals treated with DMH plus
C. parrurn have yet presented with such a
lesion. This could be interpreted as
evidence for C. parvum-induced depres-
sion of immunosurveillance.
A previous attempt at non-specific
active immunotherapy in this model using
intralesional BCG (Rogers and Gildin,
1975) did not alter the rate ofdevelopment
nor incidence of colonic tumours, but did
increase the number of metastasizing
mucinous adenocarcinomas. However, in
rats, BCG injected after the appearance
of the first tumour did enhance the
DMBA-induced mammary carcinoma
(Reddy et al., 1975) and, similarly,
methyleholanthrene-induced sarcomas
were enhanced by BCG given at the time
tumours first appeared (Lavrin et al., 1973).
The mechanism by which C. parrum
enhances cancer in our model is unknown.
Using the mouse methylcholanthrene-
induced fibrosarcoma model, Bomford
(1977) has carefully analysed the factors
allowing promotion (rather than inhibi-
tion) of tumour growth by C. parvum.
He suggests that the final outcome of
systemic C. parvurn treatment represents
the balance between tumour inhibition
by non-specific (probably macrophage-
mediated) mechanisms and tumour promo-
tion by the suppression of cell-mediated
immunity (Scott, 1972) and favours the
trapping of anti-tumour effector cells at
the site ofC. parrum deposition to account
for the latter.
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A recent review of the use of C. parvum
in over 800 cancer patients with various
cancers (Israel and Edelstein, 1977) pro-
vides encouraging data about the overall
efficacy and safety of this agent. How-
ever, the C. parvum was generally used
in combination with chemotherapy, and
patients with colonic cancer are not
specifically commented on. It may well be,
as Bomford (1977) has suggested, that the
promotional effect only arises during
non-specific immunotherapy with systemic
C. parvum alone (as in this experiment) and
only then with tumours, e.g. the colorectal
cancers of humans (Macdonald, 1976) and
rats (Sjogren and Steele, 1975) which are
sufficiently antigenic to elicit a strong
(and therefore suppressible) cell-mediated
anti-tumour response.
This work is being repeated with larger
numbers and more rigorous controls, and
sequential in vitro studies are in progress
to determine the underlying immunologi-
cal mechanisms responsible for the en-
hancementphenomenon we have observed.
However, the results of this pilot study
do suggest the need for caution in immuno-
therapy trials involving the use of C.
parvum in patients with colorectal cancer.
We thank MissNalini Singh for technicalassistance
with the histology; Miss Pippa Skevington of the
M.R.C. Statistics Unit for performing the statistical
analysis and Miss Diana Wilson for typing the
manuscript.
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